Insmed INSM ARIKAYCE external R&D expenses — R&D

Other product segments

Similar metrics at other companies

BEAMExternal Research And Development Expenses — Research And Development Expense

$30.08M-12.6%

ARVNARV-806 — Program-specific external expense

$6.5M+622%

NRIXInternal research and development expenses — R&D

$56.56M+1.6%

RAPPPreclinical Programs External Expenses — Research And Development Expense

$4.29M+32.1%

SRRKRD Expense Srk439 — Research And Development Expense

$1.76M-58.9%

GERNResearch and clinical expenses — R&D

$13M-5.1%

Questions, answered.

What is Insmed's ARIKAYCE external R&D expenses — R&D?

Insmed (INSM) reported ARIKAYCE external R&D expenses — R&D of $8.62M in Q1 2026.

How has Insmed's ARIKAYCE external R&D expenses — R&D changed year-over-year?

Insmed's ARIKAYCE external R&D expenses — R&D decreased by 28.9% year-over-year, from $12.12M to $8.62M.

What is the long-term trend for Insmed's ARIKAYCE external R&D expenses — R&D?

Over 3 years (2022 to 2025), Insmed's ARIKAYCE external R&D expenses — R&D has grown at a -12.1% compound annual growth rate (CAGR), from $61.02M to $41.44M.

What does ARIKAYCE external R&D expenses — R&D mean?

This metric captures the external research and development costs directly attributable to a specific commercialized product or therapeutic program. It encompasses third-party expenses such as clinical trial site fees, contract research organization costs, and external manufacturing development related to the asset. Monitoring this allows stakeholders to evaluate the specific cost burden of maintaining the clinical pipeline and regulatory compliance for a key revenue-generating asset.